The aim of the present study was to assess the effect of policy interventions -i.e. reimbursement decisions, guidelines and regional recommendations -on the prescribing of oral anticoagulant treatment in patients with atrial fibrillation (AF).
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT
• Novel oral anticoagulants (NOACs) are being adopted for the prevention of stroke in patients with atrial fibrillation (AF) at varying rates in different regions and countries.
• Policy interventions often have limited effects but can be improved with active implementation and feedback strategies.
WHAT THIS STUDY ADDS
• A comparison between reimbursement decisions, guidelines and regional recommendations showed that the latter caused the biggest change in the prescribing patterns of NOACs in patients with AF.
• Five years after NOACs were introduced, 60% of patients with AF were initiated on apixaban and less than 20% on warfarin.
Introduction
For many years, warfarin and other vitamin K antagonists were the only oral anticoagulants (OACs) on the market that were used for the prevention of thromboembolic complications in patients with atrial fibrillation (AF) [2, 3] . Despite the effectiveness of warfarin, there are some treatment-related drawbacks which may have contributed to underuse of this drug for stroke prevention in AF [4] . The need for continuous monitoring of coagulation, individualized patient dosing and several drug and food interactions have raised the need for the novel oral anticoagulants (NOACs) [5, 6] . NOACs have fewer treatment-related disadvantages and have been shown to be at least non-inferior to warfarin regarding efficacy and safety, and in some instances superior to warfarin in antithrombotic prophylaxis for patients with AF [7] [8] [9] . Although there are advantages relating to the apparent simplicity of treatment with the NOACs, there are some concerns about them [10] . The main concern is the risk of poor adherence as there is no regular coagulation monitoring in patients treated with NOACs [11] [12] [13] . Other concerns have been the lack of specific antidotes, although the first of these has recently become available for dabigatran [14] ; the possibilities for drug-drug interactions, which so far have been incompletely studied for NOACs; and the dependence on renal function for elimination, especially of dabigatran, considering that many high-risk AF patients are elderly and have renal impairment [15] [16] [17] .
In April 2011, dabigatran (Pradaxa®) was the first NOAC to get market approval from the European Medicines Agency (EMA) for the prevention of stroke and systemic embolism in adult patients with nonvalvular AF [15] . Later, rivaroxaban (Xarelto®) and apixaban (Eliquis®) also obtained market approval [16, 17] . Health authorities in Europe have applied different approaches to optimize the introduction of these drugs [18] . In the Stockholm region, several policy interventions might over time have influenced the introduction of the NOACs -i.e. the European guidelines [13] , the reimbursement decisions [19] [20] [21] , the national guidelines [22] and the regional Drug and Therapeutic Committee (DTC) recommendations [23] (see Box 1).
Box 1
Policy interventions during the introduction of the NOACs. The DTC makes selections among therapeutic alternatives when several alternatives are available, to increase the efficiency of pharmacotherapy in the whole healthcare system. In 2015, apixaban was recommended as the first-line NOAC along with warfarin, and dabigatran as a second-line alternative. The DTC motivated its choice, which was based on a comparative evaluation of the pivotal studies and substudies of the three NOACs on its homepage, but only in Swedish (www.janusinfo.se). Interestingly, Lip et al. later published a network meta-analysis of the major AF trials which concluded that apixaban offered the most favourable efficacy and safety profile [24] .
Globally, there is a need for effective strategies to promote rational prescribing as healthcare expenditures are rising and budgets are limited [25] . Previous studies have shown that guidelines are slowly implemented in general, but with large variation between prescribers and between healthcare systems [26] . In Sweden, the implementation of regional DTCs was regulated by law in 1997, with the aim of improving the use of evidence-based and cost-effective medicines in healthcare [27] . The Swedish DTCs develop regional recommendations that are easily available for prescribers as booklets and through decision-support systems in the medical record, and they have various educational activities (see Box 1) . Multiple activities, involving research, media and marketing, influence the prescribing of NOACs. However, the extent to which it different policy interventions have influenced the prescribing of anticoagulants in patients with AF remains unknown. The aim of the present study was to analyse the effects of reimbursement decisions, European and national guidelines, and regional DTC recommendations on prescribers' initiation of anticoagulant treatment in patients with AF in the Stockholm region.
Methods

Data source
We conducted a retrospective, population-based study using the administrative health registers of the Swedish capital
region of Stockholm County, the Stockholm Healthcare Analysis Database (SHAD; Vårdanalysdatabasen). The SHAD contains encrypted patient-level data for all 2.2 million inhabitants in the Stockholm region (gender, age, diagnoses, prescription claims, hospitalizations and other healthcare consultations, migration and death) [28] . Diagnoses have been available for secondary care since 1993, and for primary care since 2003. Prescription data, consisting of amounts, expenditures and reimbursement; the age and gender of the patient; co-payments and prescriber category, have been available since July 2010. The study was approved by the Regional Ethical Review Board in Stockholm (EPN 2015/579-31/2).
Identification of patients
We identified all patients who claimed a first prescription, issued by any prescriber, of dabigatran (ATC-code: B01AE07), rivaroxaban (ATC-codes: B01AF01 or B01AX06), apixaban (ATC-code: B01AF02) and/or warfarin (ATC-code: B01AA03) from April 2011 until February 2016. A washout period of 9 months with no claims of the substance of inclusion was applied to identify newly initiated patients on each specific drug. Patients were excluded if they met one of the following criteria: no diagnosis code for AF (ICD-code: I48) recorded by any healthcare provider in primary or secondary care from 2003 until the first claim of the respective drug; a procedure code for mechanical valves or a diagnosis code for mitral stenosis (ICD-codes: I050, I052, I342).
We examined the proportion of newly initiated patients on each drug each month. A newly initiated patient could be either a patient who was anticoagulant naïve or a one who had switched from another anticoagulant. Patients would be marked as switchers if they claimed a prescription for another anticoagulant during the 6 months prior to inclusion, and thus patients could be included several times in the analysis.
Interventions
Using interrupted times series (ITS) analyses, we linked time trends for new initiations with reimbursement decisions for the different NOACs, the inclusion of the NOACs in the regional DTC recommendations, and the adoption of NOACs in the European and national guidelines. The latter was analysed for two dates -i.e. when the preliminary and the final national guidelines, respectively, were launched (see Box 1) . For apixaban, we decided to set the reimbursement date at June 2013 as the drug was reimbursed on 29 May 2013. For the European and national guidelines and the regional DTC recommendations, we analysed their effects on the total number of NOAC initiations. As the regional DTC recommendations made a distinction between the three NOACs, we also analysed their effect on each NOAC separately. This was also done for the reimbursement decisions.
Statistical analysis
For the ITS, we used a segmented regression model with a step function to perform this [29, 30] . We fitted a least-squares regression line in each segment, with the assumption of a linear relationship between the time and the number of initiations in each month. With the Durbin-Watson test, we tested the residuals of the models for first-order autocorrelation [31] . To test for a shift in the proportions of the initiations before and after the different interventions, we included an indicator variable in the time-series model [29] . This indicator variable had a value of 0 in the months before the intervention, and a value of 1 from the month of the intervention onwards.
In the segmented regression model, we controlled for baseline levels and trends, and thereby estimated the numbers of initiations that would have taken place if the intervention had not occurred [29] . We determined the effect of an intervention in two ways: the change in level and trend after the intervention from the predictions of the model; and the effect of the intervention after 5 months. All results are given as percentages of all new initiations with either warfarin or a NOAC in that month, including switchers and anticoagulant-naïve patients alike. The effect after 5 months is given as an absolute increase in percentages. The goodness of fit of the models used is provided with the R-squared value, which is the proportion of variation explained by the statistical model, ranging from 0 to 1 [32] .
We analysed every intervention 1 year (12 data points) before and 1 year after the intervention, with monthly intervals if data were available and when no other intervention occurred within this timeframe. If it was visually clear that a timeframe shorter or longer than a year fitted the data better, we used this timeframe. Initially, we looked for a change in level after 1 month but when the level effect clearly lasted longer, the models were adapted to fit the data better. The statistical package IBM SPSS Statistics for Windows, version 23 (IBM Corp., Armonk, New York, USA) was used for all statistical analyses. Data extraction was done using SAS EG 6.1 (SAS Institute Inc., Cary, NC, USA).
Results
Patients
Of the 53 740 claims of a first prescription of the anticoagulant drugs in question, 34 165 were included for 27 942 different patients. A total of 19 090 claims were excluded as no previous diagnosis of AF was recorded for these patients, and a further 485 because the patient had recorded codes for a mechanical valve or mitral stenosis. Of the 34 165 initiations in nonvalvular AF patients, 17 559 were with warfarin, 5181 with dabigatran, 7131 with apixaban and 4294 with rivaroxaban ( Figure S1 ). For warfarin, 630 (3.6%) patients were switched from another anticoagulant treatment, and the equivalent figures were 1493 (28.8%) for dabigatran, 2474 (34.7%) for apixaban and 1626 (37.9%) for rivaroxaban.
Time trends
During the study period, a steady decrease in initiations of warfarin and increases with NOACs was observed. This seemed to commence with the European guidelines and be strengthened by the national reimbursement decisions. From May 2014, patients with AF were more likely to be initiated on a NOAC instead of on warfarin (Figure 1 ). Very few patients were switched to warfarin, while switches to NOACs increased continuously. Every July and August, there was a decrease in the total number of initiations, which coincides with the summer holidays in Sweden. The biggest change in the choice between individual NOACs occurred after apixaban was included in the regional DTC recommendations ( Figure 2) . The European and the preliminary national guidelines did not favour any particular NOAC and did not seem to have influenced choices between the NOACs, while the final national guidelines seemed to have caused a small further increase in apixaban initiations. At the end of the study period, patients with AF were more likely to be initiated on apixaban than on any other OAC, and fewer than 20% of the patients were initiated on warfarin. 
ITS
Total NOACs. The European guidelines caused both a significant positive level effect and an increase in trend, while the number of NOAC initiations was stable in the months before the intervention ( Figure 3A , Table 1 ). This resulted in a 12.5% increase in NOAC initiations 5 months after the European guidelines were issued. The national guidelines, both preliminary and final, and the regional recommendations did not result in any significant changes in total NOAC initiations after 5 months (Figure 3B-D) .
Individual NOACs. Before reimbursement, only five and 11 patients were initiated on apixaban and rivaroxaban, respectively (Figures 2, 4A) , whereas 109 patients were initiated on dabigatran. Therefore, the effect of the reimbursement of dabigatran was nonsignificant after 5 months ( Table 2 ). Initiations of apixaban and rivaroxaban increased significantly 5 months after they were reimbursed. Inclusion of apixaban as the recommended first-line NOAC together with warfarin in the DTC recommendations in the Stockholm region was associated with an increase in the proportion of patients initiated on apixaban and decreases in rivaroxaban and dabigatran initiations ( Figure 4B ). After 5 months, there was an increase of 19.5% for apixaban, and a decrease of 9.2% for rivaroxaban. Even though dabigatran was also included in the regional DTC recommendations as an alternative for selected patients, the drug showed a significant decrease of 9.5% after 5 months. Sensitivity analyses. If switched patients were excluded, the effect of the different interventions might have been different; therefore, sensitivity analyses were conducted throughout, using only the anticoagulant-naïve initiations ( Figure S2 ). This resulted in no appreciable differences (data not shown).
Discussion
In the present population-based ITS analysis, we found that the actively implemented regional DTC recommendations, the Wise List [33] , were associated with the biggest change in AF treatment during the introduction of the NOACs. The regional DTC recommendations clearly influenced decisions between the three NOACs but did not seem to have any direct effect on the decision whether to prescribe a NOAC or warfarin. After reimbursement and after the European guidelines were launched, the number of patients with nonvalvular AF initiated on warfarin decreased in favour of Figure 3 Association between the different policy interventions and novel oral anticoagulant (NOAC) initiations. (A) European guidelines; (B) preliminary national guidelines; (C) regional recommendations; D) final national guidelines. OAC, oral anticoagulant more patients being treated with a NOAC; from May 2014 onwards, patients were more likely to be initiated on a NOAC than on warfarin, and at the end of the study period, patients were more likely to be initiated on apixaban than on any other OAC. Neither the preliminary nor the final national guidelines influenced this trend.
Dabigatran was the only NOAC that was prescribed before it was reimbursed. This may have been attributable to the fact that it was the first NOAC to be launched, and that many clinicians had expressed an urgent need for alternatives to warfarin [6, 34] and therefore had not waited for the reimbursement decision. In addition, patients could have been eager to start using the NOACs. Thus, dabigatran showed the strongest increase among all NOACs in the number of users during the first few months on the market. This is in concordance with a study in Canada also finding that dabigatran was used before reimbursement, and rivaroxaban and apixaban only after reimbursement [35] .
The increase in NOAC initiations and decrease in warfarin initiations was steady throughout the study period, and commenced after the publication of the European guidelines, which is in line with previous studies in Denmark and in Ontario, Canada [36, 37] . Other studies have shown differences in the adoption of dabigatran, whereby the uptake in the US was the fastest and the uptake in the UK was the slowest, with Stockholm being intermediate [38] [39] [40] [41] .
The European Guidelines were published two months before the reimbursement of rivaroxaban and eight months after the reimbursement of dabigatran. With the current study design, it was not possible to distinguish which intervention caused the biggest increase, and therefore it is likely that it was caused by the combination of the three interventions happening within a short period of time. During the rest of the study period, neither the national guidelines (both preliminary and final) nor the regional DTC recommendations seemed to influence the steady increase in NOAC initiations, but it is not unlikely that these guidelines added to the increase indirectly.
To our knowledge, this was the first study to have used an ITS design to investigate the effect of all reimbursement decisions and guidelines on the introduction of the NOACs. Numerous factors can influence prescriber choices concerning NOACs, including research, media and marketing, but the biggest changes seem to have been captured within the models used. However, other factors, such as the market approval for idarucizumab (Praxbind®), the antidote for dabigatran, in November 2015 [14] , may also have influenced the trends. This probably contributed to the increase in initiations in dabigatran, and in NOACs overall, after the final national guidelines were published, 1 month before the market approval of the antidote.
The regional DTC recommendations caused a large change in prescribers' choice of NOAC; after 5 months, the increase in apixaban, the recommended NOAC, was even larger than the increase 5 months after it was reimbursed. This may be explained by the active implementation strategies used by the regional DTC [33] , including education, financial incentives and prescription feedback to prescribers, all of which have been proven to be effective [42] [43] [44] [45] . The present analyses thus showed that the regional implementation strategies are effective in influencing prescribers' therapeutic choices regarding anticoagulant treatment in patients with AF. These findings are in line with those of previous studies which have shown that there is high adherence to the regional DTC recommendations in Stockholm -i.e. approximately 87% in primary care and 77% in secondary care for drugs overall [33] . We may thus conclude that regional recommendations are a useful tool for influencing the prescribing of newly arrived drugs, despite all the other influences involved when they are introduced onto the market.
An ITS design has been shown to be appropriate for investigations of the effects of policy interventions, and the effects of reimbursement decisions and guidelines have been studied numerous times using this design [46, 47] . However, the use of an ITS design in the present study had some limitations. For example, the interventions took place close together in time, and the effect of one intervention may have influenced another, as was the case with the European guidelines and the reimbursement of dabigatran and rivaroxaban. Therefore, it was difficult to tell which intervention was most important for the early increase in NOAC initiations. This can also be seen for the effect of the preliminary national guidelines on the NOAC prescriptions. As apixaban was reimbursed six months before these guidelines, it looked as though the preliminary national guidelines decreased the growth of apixaban, and with that also the NOACs in general. However, a few months after reimbursement, the growth in dabigatran and rivaroxaban prescriptions diminished as well, and therefore it is unlikely that this decrease in apixaban prescriptions was caused by the preliminary national guidelines. It appears that the reimbursements of rivaroxaban and apixaban influenced the trend for dabigatran ( Figure S2 ) but as these interventions took place over a short time period, it was not possible to separate the effects. Besides the limitations in the ITS method, there were some other study limitations. Firstly, the study relied on the diagnoses recorded in healthcare records, which might have been missing in some cases. This might have led to an underestimation of the total number of patients diagnosed with AF. However, as the proportions of patients initiated with each treatment were used for the main analyses, it is unlikely that this underestimation caused any bias in the results. Secondly, the secondary care database has been well validated [48] but the validation studies for the primary care database are limited [48] . Besides that, some diagnoses from private specialists in the Stockholm region are not included, as data for these caregivers are not available in the used database.
The strength of the present study compared with previous studies of the adoption of NOACs was the use of ITS analyses, which are considered to be the strongest quasiexperimental design in intervention research [29] . We also included all patients with a nonvalvular AF diagnosis in an entire healthcare system, including both primary and secondary care, and we analysed the different NOACs separately. With this study design, we could show that the regional DTC Figure 4 Association between the reimbursement decisions (A) and the regional recommendations (B), and initiations of each oral anticoagulant (OAC) Table 2 Associations between reimbursement decisions and changes in the regional Drug and Therapeutic Committee recommendations and increases for each novel oral anticoagulant (NOAC) as percentages of all OAC initiations 
